WO2012013515A2

WO2012013515A2 - Skin patch having optimized active substance release

Info

Publication number: WO2012013515A2
Application number: PCT/EP2011/062096
Authority: WO
Inventors: Stefanie Meyer; Gitta Neufang; Julia Eckert; Karl-Heinz WÖLLER; Nils Peters;
Original assignee: Beiersdorf Ag
Priority date: 2010-07-28
Filing date: 2011-07-14
Publication date: 2012-02-02
Also published as: WO2012013515A3; DE102010032586A1

Abstract

The invention relates to a skin patch based on a damp, self-adhesive polymer film comprising a homogenous mixture of polyvinyl alcohol having a mean molar mass of 20,000 to 100,000 g/mol and a hydrolysis level of 80 to 95%, polyacrylic acid having a mean molar mass of 450,000 - 4,000,000 g/mol, and having a weight ratio of polyvinyl alcohol to polyacrylic acid in the polymer film in the range of 0:1 to 1:1, wherein the mixture comprises one or more active substances. The release of the active substance into or onto the skin takes place at a fraction of above 30 wt%, relative to the total amount of active substance used.

Description

Skin layer with optimized release of active ingredient

The skin layer is based on a moist self-adhesive polymer film comprising a homogeneous mixture of polyvinyl alcohol having an average molecular weight of 20,000 to 100,000 g / mol and a degree of hydrolysis of 80 to 95%, polyacrylic acid having an average molecular weight of 450,000 - 4,000,000 g / mol and with one

Weight ratio of polyvinyl alcohol to polyacrylic acid in the polymer film in the range of 10: 1 to 1: 1, wherein in the mixture one or more active ingredients are included.

The release of the active substance into or onto the skin takes place in a proportion of more than 30% by weight, based on the total amount of active substance used.

Wet self-adhesive polymer films are known for use as a wound dressing, as described in detail in DE 10224420 C1. In DE 10224420, the possibility of doping the wound dressing with pharmaceutical and / or cosmetic

Mentioned above.

A main requirement for cosmetic and dermatological patches, patches or pads, hereinafter collectively synonymously referred to as the skin layer, is that these on the one hand long-lasting and full-surface on the relevant. Strongly uneven

On the other hand, on sensitive skin areas such as the preferred application sites face or damaged skin, such as skin. at

Neurodermatitis, do not cause any unwanted side effects such as skin irritation and should not injure or irritate the tissue surface layer during detachment. Therefore, for corresponding patch applications, preferably those with a matrix system of hydrogels, so-called cataplasms, or silicones are used.

A disadvantage of Transdermal Therapeutic Systems (TTS), and thus also of corresponding cosmetic skin conditions, is that usually during the

Application time only about 10% to 20% of the active substance loading of the patch / patches are released (see: Commentary on the European Pharmacopoeia, Wssenschaftliche Verlagsgesellschaft Stuttgart, status: update delivery 2009).

A second major requirement of cosmetic or dermatological skin dressings is that they should deliver as soon as possible after application a maximum dose of the active substance in the desired skin layer, since the application time in some applications in the face, e.g. Wrinkle reduction, on one for cosmetic care usually

a reasonable duration, such as 30 minutes, should be limited, such as a cosmetic skin treatment. It is therefore desirable to provide corresponding skin-doped with drug, which obey this release kinetics.

New and surprising to the skilled worker, it turned out that the moist self-adhesive polymer film described in DE 10224420 C1 is very well suited not only as a wound dressing, but also due to a release rate of more than 30% as a skin layer for cosmetic use, as is often limited

Application duration specified or desired.

The skin layer according to the invention is based on a moist self-adhesive polymer film comprising a homogeneous mixture of polyvinyl alcohol having an average molecular weight of 20,000 to 100,000 g / mol and a degree of hydrolysis of 80 to 95%, polyacrylic acid having an average molecular weight of 450,000 - 4,000,000 g / mol and with a weight ratio of polyvinyl alcohol to polyacrylic acid in the polymer film in the range from 10: 1 to 1: 1 and comprising one or more, in particular cosmetic, active substances.

The release of the active substances takes place in a proportion of more than 30% by weight, based on the total mass of the active substance used.

In particular, the release of the active substances takes place in the range of up to 95% by weight, which represents a significant improvement over the release rates known from the prior art.

Although such polymer films, as shown, are known from DE 10224420 C1, such a release of more than 30% by weight is not disclosed or suggested. Also in the case of the polymer films disclosed in DE 10224420 C1 was due to their

In terms of composition and structure, analogous to the conventional transdermal therapeutic systems (TTS), only approx. 10% to 20% of the active substance load of the patch / patch would be released on the skin during the application time.

The release of the substance is understood to mean the ratio of the proportion by weight of active substance released from the polymer film to the total amount of active substance contained in the polymer film.

It is possible with the film according to the invention, a release of over 30 wt.% Wrkstoff, especially greater 40 wt.%, More than 60 wt.% And even up to 95 wt.% Possible. The invention therefore comprises, in particular, the use of the moist self-adhesive polymer film as a skin layer for the release of active substances with a release rate of more than 30% by weight, up to more than 95% by weight, based on the total amount of active substance used.

It has surprisingly been found that lipophilic as well as hydrophilic active substances from the wet self-adhesive film described with up to 95% by weight of the incorporated material are released in a significantly higher order of magnitude than in the prior art.

Such a high release rate is that of the prior art, in particular DE

10224420 C1, not shown.

Also, it is in particular certain, mostly polar and in particular cosmetic Wrkstoffe that are released from the polymer films in unpredictable orders of magnitude.

The active substance (s) are therefore preferably selected from the group Coenzyme Q10, 3- (menthoxy) propane-1,2-diol, ((1R, 2S, 5R) -N- (2- (2-pyridinyl) ethyl) - 2-isopropyl-5-methylcyclohexanecarboxamide), AGR, glycerylglucose, ibuprofen and its salts, etofenamate, indomethacin, diclofenac and its salts, acetylsalicylic acid, licochalcone A, bakuchiol, acyclovir, decanediol, carnitine, η-4-butyl-resorcinol, magnolol, Honokiol, paeonol and salicylic acid.

Not only the known parameters such as polarity and solubility as well as the molecule size influence on the dissolution of the substance, since smaller molecules generally show a better skin penetration of the active substances and matrices, but in particular also the moist self-adhesive polymer film per se as well as the layer thickness and the choice optionally added carrier material for the wet self-adhesive film, which was amazing compared to the previous findings.

The technical functionality of cosmetic patches is analogous to that of

Transdermal Therapeutic Systems (TTS). With the therapeutic difference that the active ingredient of a cosmetic patch only in the relevant

Skin layers is transported and is not provided as in a TTS through the skin systemically. Various comparative experiments were carried out to confirm the advantageous release rates shown.

Figure 1 shows the release of the drug "Premier Magnolia Super Extract 85" from different plaster systems.

In contrast to a polyisobutylene matrix (PIB), an anhydrous gel matrix (WfG) and an aqueous self-adhesive gel matrix (WG), for the cosmetic active substance Magnolia Super Extract (wax substances Magnolol and Honokiol) it was possible to add 4 to 5 times the amount of the moist adhesive according to the invention Film (FKF) are released.

The release was carried out in vitro with excised, not hardened, specially prepared dorsal skin of selected slaughter pigs (about 130 days old, about 100 kg of weight, female), which according to the literature is suitable for the estimation of (trans-) dermal absorption in humans , The experiments were carried out in glassy, at 32 ° C (skin temperature) tempered penetration chambers (Franz cell, static diffusion), the analytical detection of Wrkstoffe was carried out by HPLC. Thus, information about the distribution of the active substances between skin surface, horny layer, epidermis, dermis and receptor phase could be obtained.

Comparative composition PIB (190 g batch)

(in brackets trade name).

The active ingredient was dissolved in each case in Cetiol V and then added. Comparative composition WG (300 g batch)

The active ingredient was dissolved in each case in glycerol and then added. Comparative composition WfG (200g batch)

The active ingredient was dissolved in Lutrol E 400 and then added. Composition according to the invention FkF (250 g batch)

No. Component [%] [g]

and then added.

* The water serves only as a processing aid and is withdrawn at the end of the production '.

Figure 2 shows the release of paeonol from various plaster systems, as illustrated in Figure 1. For the cosmetic active substance paeonol, release to PIB and WfG matrices was not only significantly higher at 91.6% by weight in the case of the inventive coating (FkF), but also in the limit range of the amount of active material incorporated in the matrix.

That According to the invention, even an almost complete release of the substance is possible, which represents an unpredictable advantage in terms of the associated savings potential.

From an application point of view is also advantageous that the plaster system according to the invention for releasing a comparison with the prior art identical absolute amount Wrkstoff per time significantly thinner and thus visually inconspicuous can be designed. This is particularly important in cosmetic applications in the areas of the face and décolleté, as visually striking patches are regarded by the users as a rather undesirable eye-catcher.

Furthermore, as the thickness of the patches decreases, there is generally a greater degree of flexibility or conformability. This further advantage of the skin pads according to the invention is particularly advantageous in strongly contoured or muscular moved

Application areas, eg face or arms. In a continuous application of the conditions of the invention is also advantageous by the increased total release of active ingredient over the prior art, a longer supply of the skin with active ingredient without a change of the plaster possible.

The release of active ingredient from the polymer film (FKF) according to the invention as a percentage of the doped amount is [in% by weight]:

Paeonol and Magnolia extract can be used in patches, for example, for the cosmetic treatment of pimples due to their anti-inflammatory effect.

Paeonol is a substance extracted from the peony root or flower that is already used in traditional Chinese medicine. Paeonol inhibits the production of nitrogen monoxide and the Prostglandiens PGE ₂ and the formation of the

proinflammatory cytokines TNF-α, interleukins I L-1β and IL-6. The structure of Paenol is

Premier Magnolia Super Extract 85 is an extract of the Magnolia grandiflora root. The antiinflammatory lead substances of this extract are honokiol (60% contained in the extract) and magnolol (25% contained in the extract).

Magnolol and honokiol are already used in traditional Chinese medicine. Magnolol and honokiol, as well as paeonol, inhibit the synthesis of nitric oxide and PGE _{2 by} inhibiting the enzymes involved in the synthesis of these compounds. The structure of magnolol is,

that of Honkiol

In addition to the active ingredients, an additional carrier material applied additionally to the polymer film to the side facing away from the skin has been identified according to the invention as an influence on the release kinetics.

Thus, e.g. a carrier material consisting of an air- and water-permeable nonwoven viscose / polyester (30/70) from the company Jakob Holm in the test with the active ingredient Paeonol a significantly better release than a semi-occlusive polyurethane film (PU) as

Support material.

Figure 3 shows the release of paeonol from the same invention

wet-bonding films with different support materials.

Release rates of just over 30% by weight are determined from the skin layer with unperforated polyurethane backing. In contrast, from conditions with a carrier made of air and water permeable nonwoven viscose / polyester (30/70) a release of over 90 wt.%.

Perforating the PU film with small holes and the associated increase in water and air permeability can significantly improve the release of Paeonol in relation to the closed PU film, and is therefore also preferably to be selected carrier material, such as a nonwoven, especially a viscose / polyester Nonwoven viscose: Polyester 30: 70.

The polymer film is therefore preferably covered on one side with an air- and water-permeable carrier material. In particular, a nonwoven fabric is selected as the carrier material, in particular a viscose / polyester nonwoven, in particular with a ratio of viscose: polyester 30: 70. The prerequisite for the self-adhesive effect of the polymer film is a certain amount of moisture which is present during wound treatment by the wound fluid.

In order to be used also in cosmetic application, i. without wound fluid, self-adhesive

To develop properties, the polymer film is moistened before or for use. It is bound by the components contained polyacrylic acid and polyvinyl alcohol very strong polar water and expelled (s) or relatively weakly bound (s) drug (s) expelled from the system. It will

Surprisingly, both lipophilic and hydrophilic active substances are expelled. For lipophilic active substances, the triggering is due to the water binding; for hydrophilic active ingredients whose binding ratios play a role, but water is better bound to PAS and PVA as hydrophilic active substances, which can therefore also be released.

After moistening and during wearing, however, the polymer film also dries out from the side facing away from the skin, so that the polarity differences and, associated therewith, the release of the substance can correspondingly decrease again.

Wrd as a carrier material now, as preferred, a nonwoven material used, excess water can collect from the moistening process in the capillary systems of the nonwoven material and provide at the beginning of the application for a strong hydrophilic Polantatsüberschuss.

The associated strong reduction of Wrkstofflöslichkeit ensures a drainage of Wrkstoffs from the plaster into the skin. The water softens the stratum corneum of the skin and thus allows a better penetration of the drug through them. The active substances, such as paeonol and also the lead substances of the magnolia extract, can therefore be released from a patch with an absorbent carrier material to a greater extent than from a patch with water-repellent carrier film. The more water is given to the skin, the more permeable it becomes.

If the non-absorbent PU carrier film is perforated, the water can also penetrate into the polymer film from the back of the patch and correspondingly more active substance is released from the patch with perforated carrier film than from the patch with the non-perforated PU carrier film.

An additional advantage of the polyurethane film, which is considered to be water and gas impermeable material in principle, however, is that such a carrier material is also odor-tight. A possible odor nuisance of the user, especially in the face, by intensely smelling impurities such as Paeonol is thereby prevented, or at least reduced to an acceptable level. That is, both perforated and non-perforated support materials can be selected depending on the benefit to be achieved for the polymer films of the invention.

Furthermore, it could be stated that the thinner the moist self-adhesive polymer film, the more active substance is released with the same carrier material. A corresponding polymer film with a viscose / polyester nonwoven backing sets z. B. at a layer thickness of 0.3 mm (polymer film without support) of the wet self-adhesive polymer film after 6 hours. About 78 wt.% Of the amount used paeonol free, while at a layer thickness of 0.5 mm (polymer film without support) within the In the same period, only about 51% of the amount of active substance used is released. Preference is therefore given to a layer thickness of the polymer film (without support) in the range of 1, 5 mm to 0, 1 mm, preferably 0.5 to 0, 15 mm, particularly preferably in the range of 0.3 mm.

Also in this context, the water balance of the moist self-adhesive polymer film plays a determining role. The thinner the polymer film, the faster and more quantitatively it can absorb moisture, thereby flooding the cosmetic patch quickly and quantitatively.

In order to temporally quantify this surprising rapid flooding of impurities from the polymer film according to the invention, in a further embodiment

Eye patch for crescent-shaped application below the eyelid made and tested in an application study. Respective eye patches have the function of cooling over, overshadowing eye areas and, if necessary, using cosmetic contagious substances, such as Coenzyem Q10 or others, to reduce wrinkling. The intended duration of use of such eye patches should not exceed 30 to 45 minutes as the usual timeframe of cosmetic treatments. The tested polymer films were doped in 4 different concentrations or combinations with 3 wt.% Or 1, 5 wt.% Cosmetic cooling agents such. 3- (Menthoxy) propane-1,2-diol, manufacturer Tagasago, of the structure

And

((1R, 2S, 5R) -N- (2- (2-pyridinyl) ethyl) -2-isopropyl-5-methylcyclohexanecarboxamide; (1R, 2S, 5R) -2-isopropyl-5-methyl-N- 2- (pyridin-2-yl) ethyl) -cyclohexanecarboxyamide), manufacturer: Givaudan, of the structure

Cooling agents of this kind act via the TRPM8 receptor of the human organism and thereby produce a subjective feeling of coldness on the skin.

From the subjects (n = 11) was then subjectively the time to the onset of

Cooling and the time to maximum cooling effect determined.

On average, all subjects tested for all drug combinations

Wrkeintritt the cooling substances from the patch according to the invention out with only 1 to 3, maximum of 5 minutes. The maximum expression of the subjective cooling effect was achieved on average after 6 to 8 minutes. With these temporal

Framework conditions polymer films according to the invention are outstandingly suitable for applications as cosmetic eye patches.

The following table shows eye patch according to the invention with cooling agent (batch 200 g)

No. Component [%] [g]

1 H ₂ 0 * 48.26 96.52

Polyvinyl alcohol (Mowiol

2 18-88) 29.73 59.46

3 Carbomer (Ultrez 21) 4.00 8.00

4 PEG-8 (Lutrol E 400) 8,00 16,00 Glycerol + glyceryl

5 glucosides (Hydagen GG) 5.57 1 1, 14

6 Na carbomer 4, 14 8.28

Menthane Carboxamide

ethylpyridines

[(1R, 2S, 5R) -2-isopropyl

5-methyl-N-2- (pyridin-2-yl) ethyl) -

7 cyclohexanecarboxamide] 0.30 0.60

* The water serves only as a process aid and is withdrawn at the end of production.

The coolants are liquid and can be kneaded directly into the matrix. The homogeneous polymer matrix is then pressed to a layer thickness of 0.3 mm and back covered with a viscose / polyester nonwoven in the ratio of viscose: Polyester 30: 70 as a carrier material for the cosmetic eye patches.

In addition to the cooling agents, as further active ingredients of cosmetic patches according to the invention, e.g. but not exclusively, singly or in combination Q10, AGR, glycerylglucose, ibuprofen & its salts, etofenamate, indomethacin, diclofenac & its salts, acetylsalicylic acid, licochalcone A, bakuchiol, aciclovir, decanediol, carnitine, n-4-butyl-resorcinol and / or salicylic acid are used.

For example, η-4-butyl-resorcinol shows a release from inventive polymer film (FkF) of 63 wt.%.

For Licochalcone A, Bakuchiol, Acyclovir release modes in the claimed order of magnitude are observed.

The good release kinetics of the skin coverings according to the invention are shown in FIG. 4, which shows the dynamic release of paeonol from a moist adhesive film according to the invention on pig skin. Figure 4 shows a time-release diagram of the Paeonol from wet self-adhesive polymer film with a nonwoven carrier made of viscose / polyester. As described in detail in DE 10224420 C1, the basis of a product according to the invention is a moist self-adhesive polymer film comprising a homogeneous mixture of polyvinyl alcohol with an average molecular weight of 20,000 to 100,000 g / mol and a degree of hydrolysis of 80 to 95% and polyacrylic acid with an average Molar weight of 450,000 - 4,000,000 g / mol, wherein the weight ratio of polyvinyl alcohol to polyacrylic acid in the polymer film in the range of 10: 1 to 1: 1.

The disclosure of DE 10224420 explicitly belongs to the scope of disclosure of the present application.

To optimize the performance properties such as bond strength and pH of a cosmetic patch according to the invention were test series with

different types of use of polyvinyl alcohol (molar masses of 31,000 to 205,000 g / mol) and polyacrylic acid performed and measured the resulting patch pattern accordingly.

The highest bond strength to steel was measured at 2.09 N / cm on a polymer matrix according to the invention which consisted of partially hydrolyzed polyvinyl alcohol having a molar mass of 130,000 g / mol and a degree of hydrolysis of 87.7% (Mowiol 18/88;

Manufacturer Kuraray) and as polyacrylic acid an acrylate C 10-30 alkyl acrylate

Crosspolymer (Ultrez 21, manufacturer Noveon) in the ratio 4: 1 composed.

For use as a cosmetic patch should the moistened moist adhesive

Polymer film ideally have a pH analogous to human skin, this is usually in the range of 5.0 to 5.5.

Polyacrylic acid is acidic in water and must be neutralized to form its full viscosity in aqueous media. Triethanolamine, tromethamol, NaOH, etc. are usually used as neutralizing agents. By the addition to

Neutralizing agents, the pH of the polymer film is adjusted between 5.0 and 6.0, more preferably between 5.3 and 5.7.

Without neutralization, the pH of the patches according to the invention is about 3.4 to 4.0, depending on the polyacrylic acid used.

When neutralized with strong alkali such as NaOH, the usually coarse polyacrylic acid molecules are completely stretched, this leads to a complete hydration of the polyacrylic acid and consequently to a reduced viscosity and cohesiveness of the patch matrix, which in turn leads to a reduced bond strength of the patch. It has surprisingly been found that when 50% of the polyacrylic acid used is substituted for sodium polyacrylate, the resulting pH of the moistened patch matrix is 5.6 in the area of the human skin, but the cohesiveness is nevertheless sufficient enough to have a bond strength to steel of 1, 26 N / cm to meet the necessary application properties as a cosmetic patch and to withdraw after application without residue from the application site again.

It is therefore advantageous to exchange 50% of the polyacrylic acid used in the polymer film for sodium polyacrylate.

The production of skin layers and patches according to the invention is carried out by mixing polyacrylic acid and polyvinyl alcohol in aqueous solution. After addition and homogeneous distribution of the last component, the matrix is spread or pressed into a film and the water is removed by evaporation. The mixing process of

Starting components can be significantly accelerated by increasing the temperature up to 95 ° C.

However, it is advantageous that the active ingredients, liquid or in an appropriate solution, can be added only at the end of the mixing process and this can then take place at reduced temperature or room temperature within a very short time to homogeneity of the matrix. In this way, it is ensured that even thermally susceptible active ingredients can be easily incorporated into the matrices.

By evaporating the water or drying the film to freedom from water, two further advantages of the matrix according to the invention result.

On the one hand, a better long-term stability of the conditions according to the invention over hydrogel matrices / cataplasms of the prior art, since both the

Use components and the active ingredients during storage of the finished product are not subject to attack by hydrolytic decomposition.

On the other hand, the anhydrous products during storage need not be stabilized by the addition of preservatives against unrestrained germ growth. In times of a widespread allergy potential within the population, the possibility of dispensing with preservatives is a significant product advantage, especially for cosmetics.

Example formulations of the skin pads A to H; In percent by weight No. Component ABCDEFGH

1 H ₂ 0 ^* 49,00 47,90 51,63 50,00 50,00 50,00 50,00 50,00

Polyvinyl alcohol (Mowiol 32.00 31, 47 31, 37 32.00 20.00 26.70 35.00 32.00

2 18-88)

3 Carbomer (Ultrez 21) 4,00 4,1 1 7,00 4,00 20,00 13,30 5,00 2,50

4 PEG-8 (Lutrol E 400) - 5.08 5.00 5.00 5.00 5.00 5.00 5.00

5 propanediol 5.00 - - - - - - -

6 Na carbomer 4.00 4.1 1 - 4.00 - - - -

Menthane Carboxamide 1, 50

ethylpyridines

[(1R, 2S, 5R) -2-isopropyl

5-methyl-N-2- (pyridin-2-yl) ethyl) -

7 cyclohexanecarboxyamide]

8 4-butylresorcinol 1, 00 - - - - 1, 00 1, 00 -

9 Oleic acid 5,00 - - - - - - -

10 Glycerin - 5.08 - 4.00 4.00 4.00 4.00 5.00

Menthoxypropanediol 0.75

[3- (menthoxy) propane-

1, 2-diol]

11

12 Urea - - 5.00 - - - - 5.50

13 Paeonol - - - 1, 00 1, 00 - - -

* The water serves only as a processing aid and is withdrawn at the end of production.

Claims

claims

1. Skin support based on a moist self-adhesive polymer film comprising a

homogeneous mixture of polyvinyl alcohol having an average molecular weight of 20,000 to 100,000 g / mol and a degree of hydrolysis of 80 to 95%, polyacrylic acid having an average molecular weight of 450,000 - 4,000,000 g / mol and having a weight ratio of polyvinyl alcohol to polyacrylic acid in the Polymer film in the range of 10: 1 to 1: 1, characterized in that in the mixture one or more active substances selected from the group Coenzyem Q10, 3- (menthoxy) propane-1, 2-diol, ((1 R, 2S, 5R) -N- (2- (2-pyridinyl) ethyl) -2-isopropyl-5-methylcyclohexanecarboxamide), AGR, glyceryl glucose, ibuprofen and its salts, etofenamate, indomethacin, diclofenac and its salts, acetylsalicylic acid, licochalcone A, bakuchiol, Aciclovir, decandiol, carnitine, η-4-butyl-resorcinol, magnolol, honokiol, paeonol and salicylic acid are included.

2. Skin support according to claim 1, characterized in that the film is covered on one side with an air and water-permeable support material.

3. Skin support according to claim 2, characterized in that the carrier material is a nonwoven.

4. Skin support according to claim 3, characterized in that the fleece a

Viscose / polyester non-woven is, in particular with a ratio viscose: Polyester 30: 70.

5. Skin support according to claim 2, characterized in that the carrier material is a perforated polyurethane film.

6. Skin support according to one of the preceding claims, characterized in that the polymer film has a thickness of 0, 1 mm to 1, 5 mm, preferably 0.5 to 0, 15 mm, in particular 0.3 mm.

7. Skin support according to one of the preceding claims, characterized in that one or more neutralizing agents are added.

8. Skin support according to one of the preceding claims, characterized in that 50% of the polyacrylic acid used is replaced by sodium polyacrylate.

9. Skin support according to claim 8, characterized in that no further

Neutralizing agent is added.

10. Skin support according to one of the preceding claims, characterized in that no preservatives are added to the polymer film.

11. Use of a moist self-adhesive polymer film comprising a homogeneous mixture of polyvinyl alcohol having an average molecular weight of 20,000 to 100,000 g / mol and a degree of hydrolysis of 80 to 95%, polyacrylic acid having an average molecular weight of 450,000 - 4,000,000 g / mol and with one

Weight ratio of polyvinyl alcohol to polyacrylic acid in the polymer film in the range of 10: 1 to 1: 1 comprising at least one active ingredient as a skin layer for release of the active ingredient of more than 30 wt.%, Based on the total amount of active ingredient.

12. Use according to claim 11, characterized in that the active substance (s) are selected from the group Coenzyem Q10, 3- (menthoxy) propane-1,2-diol, ((1R, 2S, 5R) -N- (2 - (2-pyridinyl) ethyl) -2-isopropyl-5-methylcyclohexanecarboxamide), AGR, glycerylglucose, ibuprofen and its salts, etofenamate, indomethacin, diclofenac and its salts, acetylsalicylic acid, licochalcone A, bakuchiol, acyclovir, decanediol, carnitine, η 4-butyl-resorcinol, magnolol, honokiol, paeonol and salicylic acid.

13. Use according to claim 11 or 12, characterized in that the film

covered on one side with an air- and water-permeable carrier material.

14. Use according to claim 13, characterized in that the carrier material is a nonwoven.

15. Use according to claim 14, characterized in that the nonwoven a

16. Use according to claim 13, characterized in that the carrier material is a perforated polyurethane film.

17. Use according to one of claims 11 to 16, characterized in that the polymer film has a thickness of 0, 1 mm to 1, 5 mm, preferably 0.5 to 0, 15 mm, in particular 0.3 mm.

18. Use according to any one of claims 1 1 to 17 for the release of the active ingredient of over 40 wt.%, Based on the total amount of active ingredient used.

19. Use according to claim 18 for releasing the active ingredient of more than 60 wt.%, Based on the total amount of active ingredient used.

20. Use according to any one of claims 11 to 19 as eye patch.